Bio-Rad Laboratories Inc, Hercules, Calif, has added four new analytes to the company’s Liquichek tumor marker control. The updated control has received FDA premarket notification (510(k)) clearance and CE marking, and is available for the immunoassay-based tumor marker testing market. The enhanced control features HE4 and HER-2/neu. Along with these analytes, the control offers low levels of prostate-specific antigen, high levels of cancer antigens, and the protein ferritin. For more information, visit Bio-Rad Laboratories.
March 9, 2002
December 18, 2009